The impact of prior therapy with ketoconazole (keto) on clinical outcomes after subsequent docetaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) patients: Results from a randomized phase III trial (CALGB 90401).
Publication/Presentation Date
5-2012
Volume
30
Issue
15
Published In/Presented At
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
Department(s)
Administration and Leadership
Document Type
Article
COinS